| Year |
Citation |
Score |
| 2022 |
Chen WK, Oon CE, Kaur G, Sainson RCA, Li JL. Downregulation of Manic fringe impedes angiogenesis and cell migration of renal carcinoma. Microvascular Research. 104341. PMID 35157839 DOI: 10.1016/j.mvr.2022.104341 |
0.772 |
|
| 2017 |
Oon CE, Bridges E, Sheldon H, Sainson RCA, Jubb A, Turley H, Leek R, Buffa F, Harris AL, Li JL. Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth. Oncotarget. PMID 28445154 DOI: 10.18632/oncotarget.16969 |
0.762 |
|
| 2014 |
Oon CE, Bridges E, Sheldon H, Sainson RCA, Jubb A, Turley H, Leek R, Buffa F, Li JL, Harris AL. Functional comparison of Notch ligands in tumour angiogenesis Asian Pacific Journal of Tropical Disease. 4: 229. DOI: 10.1016/S2222-1808(14)60523-5 |
0.762 |
|
| 2013 |
Bazan-Peregrino M, Sainson RC, Carlisle RC, Thoma C, Waters RA, Arvanitis C, Harris AL, Hernandez-Alcoceba R, Seymour LW. Combining virotherapy and angiotherapy for the treatment of breast cancer. Cancer Gene Therapy. 20: 461-8. PMID 23846253 DOI: 10.1038/Cgt.2013.41 |
0.585 |
|
| 2011 |
Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, Wu H, Chowdhury PS, Russell AJ, Montgomery CP, Poulsom R, et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Research. 71: 6073-83. PMID 21803743 DOI: 10.1158/0008-5472.Can-11-1704 |
0.741 |
|
| 2010 |
Sheldon H, Heikamp E, Turley H, Dragovic R, Thomas P, Oon CE, Leek R, Edelmann M, Kessler B, Sainson RC, Sargent I, Li JL, Harris AL. New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood. 116: 2385-94. PMID 20558614 DOI: 10.1182/blood-2009-08-239228 |
0.749 |
|
| 2010 |
Oon C, Li J, Sainson R, Sheldon H, Turley H, Leek R, Harris A. 360 Role of DLL4 and JAG1 in tumour angiogenesis European Journal of Cancer Supplements. 8: 92. DOI: 10.1016/S1359-6349(10)71161-7 |
0.783 |
|
| 2009 |
Turley H, Steers G, Li JL, Sainson R, Harris AL, Pezzella F, Gatter KC. Corrigendum. Histopathology. 55: 463-4. PMID 19817897 DOI: 10.1111/j.1365-2559.2009.03412.x |
0.735 |
|
| 2009 |
Martinez JC, Müller MM, Turley H, Steers G, Choteau L, Li JL, Sainson R, Harris AL, Pezzella F, Gatter KC. Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 54: 598-606. PMID 19413639 DOI: 10.1111/j.1365-2559.2009.03279.x |
0.801 |
|
| 2009 |
Sheldon H, Andre M, Legg JA, Heal P, Herbert JM, Sainson R, Sharma AS, Kitajewski JK, Heath VL, Bicknell R. Active involvement of Robo1 and Robo4 in filopodia formation and endothelial cell motility mediated via WASP and other actin nucleation-promoting factors. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 513-22. PMID 18948384 DOI: 10.1096/fj.07-098269 |
0.355 |
|
| 2008 |
Williams CK, Segarra M, Sierra Mde L, Sainson RC, Tosato G, Harris AL. Regulation of CXCR4 by the Notch ligand delta-like 4 in endothelial cells. Cancer Research. 68: 1889-95. PMID 18339870 DOI: 10.1158/0008-5472.CAN-07-2181 |
0.602 |
|
| 2008 |
Sainson RC, Johnston DA, Chu HC, Holderfield MT, Nakatsu MN, Crampton SP, Davis J, Conn E, Hughes CC. TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood. 111: 4997-5007. PMID 18337563 DOI: 10.1182/Blood-2007-08-108597 |
0.478 |
|
| 2008 |
Sainson RC, Harris AL. Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis. 11: 41-51. PMID 18256896 DOI: 10.1007/s10456-008-9098-0 |
0.632 |
|
| 2008 |
Harrington LS, Sainson RC, Williams CK, Taylor JM, Shi W, Li JL, Harris AL. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvascular Research. 75: 144-54. PMID 17692341 DOI: 10.1016/j.mvr.2007.06.006 |
0.821 |
|
| 2007 |
Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA, Harris AL. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Research. 67: 11244-53. PMID 18056450 DOI: 10.1158/0008-5472.CAN-07-0969 |
0.714 |
|
| 2007 |
Sainson RC, Harris AL. Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends in Molecular Medicine. 13: 389-95. PMID 17822956 DOI: 10.1016/j.molmed.2007.07.002 |
0.563 |
|
| 2007 |
Sainson RCA, Li J, Harrington L, Shi W, Heikamp E, Leek R, Harris AL. In vivo assessment of Delta like‐4 function in tumour development The Faseb Journal. 21. DOI: 10.1096/fasebj.21.5.a16 |
0.727 |
|
| 2006 |
Sainson RC, Harris AL. Hypoxia-regulated differentiation: let's step it up a Notch. Trends in Molecular Medicine. 12: 141-3. PMID 16513423 DOI: 10.1016/j.molmed.2006.02.001 |
0.448 |
|
| 2006 |
Sainson RC, Conn EM, Chu HC, Brown J, Aoto JN, Nakatsu MN, Hughes CC. Bi-directional signaling through notch and jagged controls the phenotype of angiogenic endothelial cells Vascular Pharmacology. 45: e112. DOI: 10.1016/J.Vph.2006.08.303 |
0.429 |
|
| 2006 |
Sainson RC, Harrington L, Shi W, Li JL, Williams C, Harris AL. Delta-Like 4 signaling regulates endothelial and surrounding cells' plasticity and cell fate determination during vascular development Vascular Pharmacology. 45: e43. DOI: 10.1016/j.vph.2006.08.185 |
0.752 |
|
| 2005 |
Sainson RC, Aoto J, Nakatsu MN, Holderfield M, Conn E, Koller E, Hughes CC. Cell-autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 19: 1027-9. PMID 15774577 DOI: 10.1096/Fj.04-3172Fje |
0.478 |
|
| 2004 |
Sainson RC, Nakatsu M, Aoto J, Holderfield M, Hughes CC. CHARACTERIZATION OF NOTCH SIGNALING FUNCTIONS DURING ANGIOGENESIS USING A NOVEL IN VITRO TUBE FORMING ASSAY. Cardiovascular Pathology. 13: 62. DOI: 10.1016/J.Carpath.2004.03.183 |
0.337 |
|
| 2003 |
Nakatsu MN, Sainson RC, Pérez-del-Pulgar S, Aoto JN, Aitkenhead M, Taylor KL, Carpenter PM, Hughes CC. VEGF(121) and VEGF(165) regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model. Laboratory Investigation; a Journal of Technical Methods and Pathology. 83: 1873-85. PMID 14691306 DOI: 10.1097/01.Lab.0000107160.81875.33 |
0.472 |
|
| 2003 |
Nakatsu MN, Sainson RC, Aoto JN, Taylor KL, Aitkenhead M, Pérez-del-Pulgar S, Carpenter PM, Hughes CC. Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvascular Research. 66: 102-12. PMID 12935768 DOI: 10.1016/S0026-2862(03)00045-1 |
0.383 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2020 |
Sainson RCA, Thotakura AK, Kosmac M, Borhis G, Parveen N, Kimber R, Carvalho J, Henderson SJ, Pryke KL, Okell T, O'Leary S, Ball S, Van Krinks C, Gamand L, Taggart E, et al. An antibody targeting ICOS increases intratumoral cytotoxic to regulatory T cell ratio and induces tumor regression. Cancer Immunology Research. PMID 32999002 DOI: 10.1158/2326-6066.CIR-20-0034 |
0.261 |
|
| 2017 |
Xie B, Tomaszewski MR, Neves A, Ros S, Hu DE, McGuire S, Mullins SR, Tice DA, Sainson RCA, Bohndiek SE, Wilkinson RW, Brindle KM. Optoacoustic detection of early therapy-induced tumor cell death using a targeted imaging agent. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28821560 DOI: 10.1158/1078-0432.Ccr-17-1029 |
0.247 |
|
| 2017 |
Hoffman F, Gavaghan D, Osborne J, Barrett IP, You T, Ghadially H, Sainson R, Wilkinson RW, Byrne HM. A Mathematical Model of Antibody-Dependent Cellular Cytoxicity (ADCC). Journal of Theoretical Biology. PMID 28970093 DOI: 10.1016/j.jtbi.2017.09.031 |
0.243 |
|
| 2014 |
Leishman A, Harris O, Ulrichsen JC, Harper J, Popple A, Papaspyridonos M, Williams G, Mullins S, Valge-Archer V, Stewart R, Sainson R, Morrow M, Wilkinson R. Abstract 1651: Profiling immune cells within the tumor microenvironment for optimal model selection for pre-clinical investigations Cancer Research. 74: 1651-1651. DOI: 10.1158/1538-7445.Am2014-1651 |
0.227 |
|
| 2019 |
Quaratino S, Sainson R, Thotakura A, Henderson SJ, Pryke K, Newton A, Brennan N, Oelmann E. A first-in-human study of KY1044, a fully human anti-ICOS IgG1 antibody as monotherapy and in combination with atezolizumab in patients with selected advanced malignancies. Journal of Clinical Oncology. 37: TPS2644-TPS2644. DOI: 10.1200/JCO.2019.37.15_SUPPL.TPS2644 |
0.217 |
|
| 2014 |
Harper J, Sainson RCA. Regulation of the anti-tumour immune response by cancer-associated fibroblasts Seminars in Cancer Biology. 25: 69-77. PMID 24406209 DOI: 10.1016/j.semcancer.2013.12.005 |
0.214 |
|
| 1999 |
Perbal B, Martinerie C, Sainson R, Werner M, He B, Roizman B. The C-terminal domain of the regulatory protein NOVH is sufficient to promote interaction with fibulin 1C: a clue for a role of NOVH in cell-adhesion signaling. Proceedings of the National Academy of Sciences of the United States of America. 96: 869-74. PMID 9927660 DOI: 10.1073/Pnas.96.3.869 |
0.212 |
|
| 2016 |
Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, Ahdesmaki MJ, Leyland R, Mullins S, Pacelli L, Marcus D, Anderton J, Watkins A, Coates Ulrichsen J, Brohawn P, et al. Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunology Research. PMID 27923825 DOI: 10.1158/2326-6066.Cir-16-0114 |
0.208 |
|
| 2021 |
Lin C, Naing A, Patel MR, Burris III HA, Curigliano G, Thistlethwaite F, Minchom AR, Ascierto PA, De Braud FG, Eder JP, Wake M, Palu CC, Newton AL, Deantonio C, Hanekom W, ... Sainson RC, et al. KY1044 to target the ICOS pathways inducing intratumoral Treg depletion and agonism of effector T cells: Preliminary pharmacodynamic markers from a phase 1/2 multicenter trial. Journal of Clinical Oncology. 39: 2626-2626. DOI: 10.1200/JCO.2021.39.15_SUPPL.2626 |
0.204 |
|
| 2016 |
Chypre M, Seaman J, Cordeiro OG, Willen L, Knoop KA, Buchanan A, Sainson RC, Williams IR, Yagita H, Schneider P, Mueller CG. Characterization and application of two RANK-specific antibodies with different biological activities. Immunology Letters. 171: 5-14. PMID 26773232 DOI: 10.1016/j.imlet.2016.01.003 |
0.195 |
|
| 2022 |
Lu LC, Deantonio C, Palu CC, Lee YH, Mitchell LS, Cowan M, Corser M, Sherry L, Cheng AL, Quaratino S, Shao YY, Sainson RCA, Hsu CH. ICOS-positive regulatory T cells in hepatocellular carcinoma: the perspective from digital pathology analysis. Oncology. PMID 35709702 DOI: 10.1159/000525239 |
0.188 |
|
| 2017 |
Ghadially H, Brown L, Lloyd C, Lewis L, Lewis A, Dillon J, Sainson R, Jovanovic J, Tigue NJ, Bannister D, Bamber L, Valge-Archer V, Wilkinson RW. MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue. British Journal of Cancer. PMID 28334733 DOI: 10.1038/bjc.2017.79 |
0.168 |
|
| 2017 |
Xie B, Tomaszewski M, Neves AA, Mullins SR, Tice D, Sainson R, Bohndiek S, Wilkinson RW, Brindle KM. Abstract 2866: Volumetric optoacoustic imaging of tumor cell death using a targeted imaging agent Cancer Research. 77: 2866-2866. DOI: 10.1158/1538-7445.Am2017-2866 |
0.152 |
|
| 2022 |
Viveiros N, Flores BC, Lobo J, Martins-Lima C, Cantante M, Lopes P, Deantonio C, Palu C, Sainson RC, Henrique R, Jerónimo C. Detailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies. Clinical & Translational Immunology. 11: e1402. PMID 36092481 DOI: 10.1002/cti2.1402 |
0.146 |
|
| 2008 |
Sainson RC. Angiogenesis: an integrative approach from science to medicine The Lancet Oncology. 9: 1035-1036. DOI: 10.1016/S1470-2045(08)70274-2 |
0.122 |
|
| 2007 |
Pedram A, Razandi M, Sainson RC, Kim JK, Hughes CC, Levin ER. A conserved mechanism for steroid receptor translocation to the plasma membrane. The Journal of Biological Chemistry. 282: 22278-88. PMID 17535799 DOI: 10.1074/jbc.M611877200 |
0.118 |
|
| 2021 |
Patel MR, Naing A, Burris III HA, Lin C, Curigliano G, Thistlethwaite F, Minchom AR, Ascierto PA, De Braud FG, Cecchini M, Hanekom W, Sainson RC, Wilson RJ, Quaratino S. A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies. Journal of Clinical Oncology. 39: 2624-2624. DOI: 10.1200/JCO.2021.39.15_SUPPL.2624 |
0.097 |
|
| 2022 |
Yap T, LoRusso PM, Wong DJ, Hu-Lieskovan S, Papadopoulos KP, Holz JB, Grabowska U, Gradinaru C, Leung KM, Marshall S, Reader CS, Russell R, Sainson RCA, Seal CJ, Shepherd CJ, et al. A Phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36342102 DOI: 10.1158/1078-0432.CCR-22-1449 |
0.092 |
|
| 2005 |
Griffith CK, Miller C, Sainson RC, Calvert JW, Jeon NL, Hughes CC, George SC. Diffusion limits of an in vitro thick prevascularized tissue. Tissue Engineering. 11: 257-66. PMID 15738680 DOI: 10.1089/Ten.2005.11.257 |
0.077 |
|
| Hide low-probability matches. |